TABLE 3

Patient characteristics of the analysis of second-line chemotherapy

AEAS#SAS#
Subjects278180
Age years median (range)69 (38–85)69 (38–83)
Sex
 Male239 (86.0%)154 (85.6%)
 Female39 (14.0%)26 (14.4%)
Histology
 AdC101 (36.3%)70 (38.9%)
 SqCC70 (25.2%)51 (28.3%)
 AdSqC1 (0.4%)1 (0.6%)
 NSCLC (NOS)32 (11.5%)14 (7.8%)
 SmCC74 (26.6%)44 (24.4%)
Pattern of IIPs
 UIP146 (52.5%)89 (49.4%)
 Non-UIP103 (37.1%)66 (36.7%)
 Unclassified29 (10.4%)25 (13.9%)

AEAS: acute exacerbation analysis set; SAS: survival analysis set; AdC: adenocarcinoma; SqCC: squamous cell carcinoma; AdSqC: adenosquamous carcinoma; NSCLC: nonsmall cell lung cancer; NOS: not otherwise specified; SmCC: small cell carcinoma; IIP: idiopathic interstitial pneumonia; UIP: usual interstitial pneumonia. #: AEAS was evaluated for acute exacerbation and objective response by second-line chemotherapy; SAS consisted of patients for which analysable survival information could be obtained.